Long-Term Outcome of Merkel Cell Carcinoma After Avelumab Exposure

From General Health to Specialized Oncology

Keys Medical Center has long championed general health and science information, emphasizing preventive care, wellness, and accessible medical services. This foundation prioritizes patient education and holistic approaches to maintaining health. In this context, discussions of disease risk and treatment outcomes are typically framed around lifestyle factors and routine clinical management. Transitioning from this broad perspective, the focus narrows to the implications of specific pharmaceutical exposures. In particular, the long-term prognosis of Merkel Cell Carcinoma (MCC) following Avelumab treatment represents a distinct area of inquiry. This shift moves beyond general health maintenance to examine how targeted therapeutic agents may influence disease trajectories. The occupational exposure concern arises when considering that individuals in certain work environments might encounter risk factors that intersect with the use of such immunotherapies. Thus, the conversation pivots from general health stewardship to a nuanced evaluation of how Avelumab exposure, in the context of MCC, necessitates careful monitoring of long-term outcomes, especially for those with potential occupational vulnerabilities.

Avelumab: Mechanism and Approval in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Long-Term Outcomes and Refractory Disease

The long-term prognosis for patients with Merkel cell carcinoma after avelumab exposure is variable. While avelumab can induce durable responses in some patients, the overall prognosis remains poor for those who do not respond or who relapse. In a retrospective multicenter study conducted at three academic sites in Germany, five patients with metastatic MCC refractory to avelumab were subsequently treated with combined ipilimumab and nivolumab. Three out of five patients responded to this combination according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A larger multicenter study from the prospective skin cancer registry ADOREG similarly reported that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study further noted that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab. The hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger or exacerbate underlying autoimmune or granulomatous conditions.

Risk Context and Clinical Considerations

Regarding the adequacy of warnings, the evidence indicates that avelumab's approval and clinical use are supported by trial data showing efficacy in a subset of patients, but also that a substantial proportion of patients do not respond or become refractory. The risk of progression on therapy is approximately 50% (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who progress, alternative treatments such as ipilimumab plus nivolumab may offer benefit, but data are limited to small retrospective series (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The timeline between avelumab exposure and documented harm is variable; immune-related adverse events can occur during treatment, and progression may occur after initial response or as primary resistance. The evidence does not provide a specific latency period for harm, but rather emphasizes that avelumab-refractory disease is a recognized clinical scenario with limited subsequent options. Prognosis-related considerations for affected patients are sobering. MCC is inherently aggressive, and while avelumab can induce durable responses in some patients, the overall prognosis remains poor for those who do not respond or who relapse. The availability of subsequent therapies, such as ipilimumab plus nivolumab, may improve outcomes in a subset of avelumab-refractory patients, but this is based on small sample sizes (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). Patients and clinicians should be aware of the risk of immune-related adverse events and the potential need for alternative immunotherapy combinations. In summary, avelumab is a valuable treatment for metastatic MCC, but its use is associated with a significant risk of progression and immune-related adverse events. The evidence underscores the need for careful patient selection, monitoring for irAEs, and planning for subsequent therapy in refractory cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for Merkel cell carcinoma after avelumab treatment?

The long-term prognosis is variable. While avelumab can induce durable responses in about one-third of patients with metastatic MCC, approximately 50% of patients progress on therapy. For those who become refractory, subsequent treatments like ipilimumab plus nivolumab may offer benefit in a subset, but data are limited. Overall, MCC remains an aggressive disease with high recurrence and mortality rates.

What are the risks of immune-related adverse events with avelumab?

Avelumab can cause overactivation of the immune system, leading to immune-related adverse events (irAEs). One reported case involved hypercalcemia due to reactivation of sarcoidosis, which was managed with corticosteroids. Patients should be monitored for irAEs during treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.